Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One SNP in the MAPK14 (rs851023) was significantly associated with incident PCa risk.
|
31667711 |
2019 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of COPS3 inhibited the progress of PCa through reducing the levels of phosphorylated P38 MAPK and impaired the epithelial-mesenchymal transition process.
|
31509289 |
2019 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of lncRNA PVT1 expression inhibits proliferation and migration by regulating p38 expression in prostate cancer.
|
30250582 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meanwhile, we demonstrate that p38 MAPK pathway is involved in PAC-320 induced antiproliferative activities in prostate cancer.
|
29416632 |
2018 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
CD44 collaborates with ERBB2 mediate radiation resistance via p38 phosphorylation and DNA homologous recombination pathway in prostate cancer.
|
29894706 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The chrysin-mediated intracellular signaling pathways suppressed phosphoinositide 3-kinase (PI3K) and the abundance of AKT, P70S6K, S6, and P90RSK proteins, but stimulated mitogen-activated protein kinases (MAPK) and activation of ERK1/2 and P38 proteins in the prostate cancer cells.
|
28213961 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> These data suggest that exenatide and liraglutide attenuate prostate cancer growth through regulating P38 pathway by binding with GLP-1R.
|
28008585 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Function of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.
|
26919443 |
2016 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results reveal that p38 MAPK regulates DKK-1 in prostate cancer and may present a potential target in osteolytic prostate cancers.
|
26913608 |
2016 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
|
24080497 |
2014 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, these mitogen-activated protein kinase activities were also triggered by re-expressed E-cadherin leading to p38 and ERK1/2 activity in PCa cells; these signals provide protection to PCa cells upon challenge with chemotherapy and cell death-inducing cytokines.
|
24619413 |
2014 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
|
23255296 |
2013 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the diagnostic and prognostic between NOB1 and p38 MAPK in prostate cancer (PCa) tissue after radical prostatectomy, the hypothesis that prostate cancers with NOB1 expression have distinct clinical, prognostic and molecular attributes was tested.
|
24228091 |
2013 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We herein demonstrate that the cross-linking of cell surface PSMA with specific antibodies activates the small GTPases RAS and RAC1 and the MAPKs p38 and ERK1/2 in prostate carcinoma LNCaP cells.
|
19242540 |
2009 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that VES-induced expression of NAG-1 mRNA/protein is regulated by transcriptional/post-transcriptional mechanism in a p38 kinase-dependent manner and NAG-1 can be chemopreventive/therapeutic target in prostate cancer.
|
18413810 |
2008 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of the present study suggest that LPA, the receptor LPA(1), ERK2 and p38alpha are important regulators for prostate cancer cell invasion and thus could play a significant role in the development of metastasis.
|
17531530 |
2007 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways.
|
16956884 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer.
|
16407830 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D.
|
16618780 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
From these results, hypoxia increased tumor cell invasion by up-regulating uPAR expression, which might be mediated through ERK and p38 kinase signaling pathways in PC3MLN4 prostate cancer cell line.
|
15031672 |
2004 |